Program Perspectives in Cell- and Gene-Based Medicines - DGTI
Program Perspectives in Cell- and Gene-Based Medicines - DGTI
Program Perspectives in Cell- and Gene-Based Medicines - DGTI
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
P7.07 Activation of allogeneic NK cells to overcome tumour immune<br />
escape<br />
Eileen Auth, Frankfurt<br />
P7.08 Kir+ NK cells show <strong>in</strong>creased degranulation activity <strong>in</strong> KIR-HLA<br />
mismatch situations post-stem cell transplantation<br />
Petra Becker, Frankfurt<br />
P7.09 Influence of the Immunosuppressive Drug Mycophenolate Mofetil on<br />
NK cell Functionality after Haploidentical Stem <strong>Cell</strong> Transplantation<br />
Claudia Brehm, Frankfurt<br />
P7.10 CTLA-4 antibodies Tremelimumab <strong>and</strong> Ipilimumab overcome<br />
tumor-mediated immunsuppressive effects of CTLA-4 on human<br />
dendritic cells<br />
Katr<strong>in</strong> Göpfert, Ma<strong>in</strong>z<br />
P7.11 Inhibition of tumor immune escape from NKG2D-dependent NK<br />
cell cytotoxocity<br />
Ariane Groth, Frankfurt<br />
P7.12 Sk<strong>in</strong> trigger<strong>in</strong>g of TLR7 modulates respiratory dendritic cells <strong>and</strong><br />
natural killer cells<br />
Nelli Baal, Giessen<br />
P7.13 Development of a killer cell immunoglobul<strong>in</strong> like receptor (KIR) typ<strong>in</strong>g<br />
assay<br />
Johannes Hennecke, Frankfurt<br />
P7.14 A soluble fragment of the NKp30 lig<strong>and</strong> BAG-6 <strong>in</strong>hibites NK cell<br />
cytotoxicity<br />
Jan<strong>in</strong>a Kaudeer, Frankfurt<br />
P7.15 Antigen-specific TCR-modified Treg for treatment of EAE<br />
Elisa Kieback, Berl<strong>in</strong><br />
P7.16 <strong>Gene</strong>tically Modified Natural Killer <strong>Cell</strong>s that Express a<br />
Tumor-specific Granzyme B Fusion Prote<strong>in</strong><br />
Pranav Oberoi, Frankfurt<br />
P7.17 Characterization of primary <strong>and</strong> exp<strong>and</strong>ed NK cells<br />
Sab<strong>in</strong>e Müller, Bergisch Gladbach<br />
P7.18 Fully reversible Fab-Streptamer reagents for cl<strong>in</strong>ical cell therapy<br />
Christian Stemberger, Munich<br />
37
Change language